Contraception Clinical Trial
Official title:
Randomized Trial of Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device After Vaginal Delivery
This study is a randomized controlled trial comparing 6 month usage rates of the levonorgestrel-releasing intrauterine device (LNG-IUD) when inserted postplacentally after vaginal delivery or delayed placement at 6-8 weeks postpartum. Given the high rate of unintended pregnancy in the United States, particularly in postpartum women, there is a need for reliable, effective, long-term contraception such as the IUD in postpartum women. Postplacental insertion of intrauterine contraception would help to address this need. The primary hypothesis of this study is that use of the LNG-IUD at 6 months after vaginal delivery will be higher in women who have immediate postplacental insertion as compared to delayed insertion 6-8 weeks following delivery.
The United States (US) has the highest unintended pregnancy rate of any developed country.
Of the 6.4 million pregnancies in the US each year, almost half are unintended (49%).
Roughly half of these (22% of all pregnancies) result in unintended births, while 20% of all
pregnancies result in abortion. Postpartum women are particularly susceptible, with an
unintended pregnancy rate of 10%-44% in the first year postpartum. These unintended
pregnancies occur despite the recommendation that a contraceptive method be selected prior
to hospital discharge.
Given the high rate of unintended pregnancy in the United States, particularly in postpartum
women, there is a need for reliable, effective, long-term contraception such as the IUD in
postpartum women. Postplacental insertion of intrauterine contraception would help to
address this need. The IUD is a highly effective but underused method of postpartum
contraception. Although the expulsion rate in postplacental insertion is higher than
interval insertion, the benefits of highly effective contraception available immediately
after delivery may outweigh the risks of expulsion.
To date, there have been no randomized trials of postplacental insertion of the LNG-IUD in
the United States. One pilot study in the United States of 20 subjects who received an
ultrasound-guided postplacental insertion of the LNG-IUD showed an acceptable expulsion rate
of 10% and no infections over a 10-week follow-up, thus making postplacental insertion of
LNG-IUD safe for further study.
This study is a randomized controlled trial comparing 6 month usage rates of the
levonorgestrel-releasing intrauterine device (LNG-IUD) when inserted postplacentally after
vaginal delivery or delayed placement at 6-8 weeks postpartum. One hundred sixty-eight women
receiving prenatal care at Magee-Womens Hospital, Pittsburgh, PA, who are interested in
using the LNG-IUD for contraception will be enrolled during their pregnancy. The IUD will be
inserted within 10 minutes after delivery of the placenta in women randomized to immediate
insertion. Delayed IUD insertion will be performed at the first postpartum visit in 6-8
weeks. All subjects will follow up in person at 6-8 weeks and 6 months after delivery. A
telephone interview will occur at 3 months after delivery for all subjects.
Subjects who are not eligible for insertion due to post-randomization ineligibility criteria
will be referred to their primary gynecologist or midwife for delayed IUD placement. They
will be contacted by phone at 3 and 6 months to assess quality of life, contraceptive usage,
and unintended pregnancy rates.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |